+1 (629)348-3199Special Issue Article - Journal of Diabetology (2021) Volume 5, Issue 1
Cardiovascular Disease (CVD) and Diabetes-Know Your Risk-Is it Time for a Paradigm Shift?
CVD may be a major complication of diabetes and therefore the leading explanation for early death among people with diabetes—about 65 percent of individuals with diabetes die from heart condition and stroke. Annually within the us 1, 000, 000 people will suffer a myocardial infarction: one-third of these will occur in people that have already suffered an occasion . Modification of traditional risk factors, like smoking cessation, decreasing vital sign , and lowering of cholesterol in high-risk individuals, has resulted in reducing CVD and stroke remarkably. However, the present standard of care using traditional modifiable risk factors alone is usually inadequate to spot some individuals with CVD. Therefore, it is vital to not rely solely on risk factor modification when assessing for CVD, but also to incorporate a disease platform. A new paradigm that specialize in the disease (atherosclerosis) is important . Noninvasive endothelial testing [coronary calcium score (CCS), carotid intima media thickness (cIMT)], genetics assessment [Apolipoprotein E (ApoE), kinesin-like protein 6 (KIF6), 9 region p21 locus (9p21), lipoprotein(a) (LPA), and haptoglobin genotype (Hp 1-1, Hp 1-2, Hp 2-2)], and measurement of major biomarkers [F2-Isoprostanes (F2-IsoPs), high-sensitivity C-reactive protein (hs-CRP), urine albumin creatinine ratio (UACR), myeloperoxidase (MPO), lipoprotein-associated phospholipase A2 (Lp-PLA2), fibrinogen, and homocysteine (Hcy)] enhance the power to spot disease (atherosclerosis) earlier. When disease is found, the causes must be identified and treated. A paradigm shift that specialize in arteriology (disease platform) is remitted to scale back the high rate of recurrence of CVD and stroke.